Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CAPLACIZUMAB-YHDP Cause Condition aggravated? 60 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 60 reports of Condition aggravated have been filed in association with CAPLACIZUMAB-YHDP. This represents 4.3% of all adverse event reports for CAPLACIZUMAB-YHDP.

60
Reports of Condition aggravated with CAPLACIZUMAB-YHDP
4.3%
of all CAPLACIZUMAB-YHDP reports
9
Deaths
28
Hospitalizations

How Dangerous Is Condition aggravated From CAPLACIZUMAB-YHDP?

Of the 60 reports, 9 (15.0%) resulted in death, 28 (46.7%) required hospitalization, and 2 (3.3%) were considered life-threatening.

Is Condition aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CAPLACIZUMAB-YHDP. However, 60 reports have been filed with the FAERS database.

What Other Side Effects Does CAPLACIZUMAB-YHDP Cause?

Product use in unapproved indication (465) Adamts13 activity decreased (136) Off label use (133) Platelet count decreased (126) Epistaxis (123) Fatigue (110) Contusion (86) Injection site pain (74) Headache (71) Adamts13 activity abnormal (63)

What Other Drugs Cause Condition aggravated?

TOFACITINIB (16,925) INFLIXIMAB (16,616) DUPILUMAB (16,459) ETANERCEPT (15,897) METHOTREXATE (14,938) ADALIMUMAB (13,527) PREDNISONE (10,751) INFLIXIMAB-DYYB (10,275) HYDROXYCHLOROQUINE (8,848) RITUXIMAB (8,627)

Which CAPLACIZUMAB-YHDP Alternatives Have Lower Condition aggravated Risk?

CAPLACIZUMAB-YHDP vs CAPMATINIB CAPLACIZUMAB-YHDP vs CAPREOMYCIN CAPLACIZUMAB-YHDP vs CAPSAICIN CAPLACIZUMAB-YHDP vs CAPTOPRIL CAPLACIZUMAB-YHDP vs CARBAMAZEPINE

Related Pages

CAPLACIZUMAB-YHDP Full Profile All Condition aggravated Reports All Drugs Causing Condition aggravated CAPLACIZUMAB-YHDP Demographics